Loss of c-REL but not NF-κB2 prevents autoimmune disease driven by FasL mutation

Area of Science:

• Immunology
• Molecular Biology
• Autoimmunity

Background:

• FASL/FAS signaling is crucial for preventing autoimmune disease and lymphadenopathy.
• Mutant mice lacking membrane-bound FASL (FasL(Δm/Δm)) develop autoimmune conditions, including glomerulonephritis.
• Elevated NF-κB-regulated cytokine levels in FasL(Δm/Δm) mice suggest a role for NF-κB-dependent inflammation in disease pathogenesis.

Purpose of the Study:

• To investigate the role of NF-κB signaling in the autoimmune disease observed in FasL(Δm/Δm) mice.
• To determine the therapeutic potential of inhibiting specific NF-κB pathways, namely canonical (c-Rel) and non-canonical (NF-κB2), in this autoimmune model.

Main Methods:

• Genetic manipulation of FasL(Δm/Δm) mice to delete either the c-Rel or NF-κB2 genes.
• Assessment of autoimmune parameters, including lymphadenopathy, autoantibodies, cytokine levels, and survival rates.
• Evaluation of regulatory T-cell populations in the context of c-Rel deficiency.

Main Results:

• Deletion of NF-κB2 partially reduced inflammatory cytokines and autoantibodies but led to exacerbated lymphoproliferative disease and minor survival benefit.
• Loss of c-Rel in FasL(Δm/Δm) mice resulted in significantly increased lifespan and reduced autoimmune pathology, including lower cytokine and autoantibody levels.
• Reduced regulatory T-cell numbers in c-Rel deficient mice did not worsen autoimmunity.

Conclusions:

• Selective inhibition of c-Rel ameliorates autoimmune disease in the context of FasL/FAS signaling defects.
• Targeting c-Rel offers a potential therapeutic strategy for autoimmune pathologies associated with FasL/FAS deficiency, potentially avoiding complications of broad NF-κB inhibition.